Department of Neurology, Baylor College of Medicine, 7200 Cambridge St Suite 9A, Houston, TX, 77030, USA.
Department of Pharmacy, Memorial Hermann the Woodlands Medical Center, The Woodlands, TX, USA.
Adv Ther. 2023 May;40(5):2097-2115. doi: 10.1007/s12325-023-02494-1. Epub 2023 Mar 25.
Cardiac arrest (CA) is a critical public health issue affecting more than half a million Americans annually. The main determinant of outcome post-CA is hypoxic-ischemic brain injury (HIBI), and temperature control is currently the only evidence-based, guideline-recommended intervention targeting secondary brain injury. Temperature control is a key component of a post-CA care bundle; however, conflicting evidence challenges its wide implementation across the vastly heterogeneous population of CA survivors. Here, we critically appraise the available literature on temperature control in HIBI, detail how the evidence has been integrated into clinical practice, and highlight the complications associated with its use and the timing of neuroprognostication after CA. Future clinical trials evaluating different temperature targets, rates of rewarming, duration of cooling, and identifying which patient phenotype benefits from different temperature control methods are needed to address these prevailing knowledge gaps.
心脏骤停(CA)是一个严重的公共卫生问题,每年影响超过 50 万美国人。CA 后结局的主要决定因素是缺氧缺血性脑损伤(HIBI),而体温控制是目前针对继发性脑损伤的唯一基于证据、指南推荐的干预措施。体温控制是 CA 后护理包的关键组成部分;然而,相互矛盾的证据挑战了其在 CA 幸存者这一极其异质人群中的广泛实施。在这里,我们批判性地评估了关于 HIBI 中体温控制的现有文献,详细说明了证据如何融入临床实践,并强调了使用体温控制的相关并发症以及 CA 后神经预后的时机。需要未来的临床试验来评估不同的体温目标、复温速率、冷却持续时间,并确定哪种患者表型从不同的体温控制方法中受益,以解决这些普遍存在的知识空白。